Curis (CRIS) AI Stock Analysis

1,452 Followers

Top Page

Curis

(NASDAQ:CRIS)

39Underperform

Curis's stock score reflects significant financial instability, with persistent losses and negative cash flows being major concerns. Weakness in technical indicators and a negative P/E ratio further contribute to the low score. While the earnings call provided some optimism with positive clinical progress, the ongoing financial challenges and reliance on partnerships weigh heavily on the overall assessment.

Positive Factors

Clinical Trials

The TakeAim Lymphoma study is now registrational, evaluating emavusertib as a promising treatment for acute myeloid leukemia and non-Hodgkin’s lymphoma.

Regulatory Approval

Curis had successful meetings with the FDA and EMA, supporting a potential accelerated approval path for emavusertib in primary CNS lymphoma.

Revenue and Earnings

Curis reported revenue and EPS that were better than the estimates.

Negative Factors

Financial Risk

The price target is being lowered due to dilution from a recent raise, which could impact the stock's valuation.

Stock Valuation

The price target is being lowered to $20 from $26 due to dilution from the offering.

Curis (CRIS) vs. S&P 500 (SPY)

Market Cap

$12.24M

Dividend YieldN/A

Average Volume (3M)68.47K

Price to Earnings (P/E)―

Beta (1Y)2.67

Revenue Growth8.83%

EPS Growth22.06%

CountryUS

Employees49

SectorHealthcare

Sector Strength70

IndustryBiotechnology

Share Statistics

EPS (TTM)-7.03

Shares Outstanding10,462,250

10 Day Avg. Volume127,478

30 Day Avg. Volume68,466

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)2.20

Price to Cash Flow (P/CF)-1.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$14.00

Price Target Upside1096.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Curis Business Overview & Revenue Model

Company DescriptionCuris, Inc. (CRIS) is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company is engaged in the research and development of drug candidates aimed at addressing unmet medical needs in oncology. Curis leverages its scientific expertise in small molecule drug discovery and development to advance its pipeline of proprietary drug candidates.

How the Company Makes MoneyCuris primarily makes money through the development and commercialization of its proprietary drug candidates, focusing on oncology therapies. The company generates revenue from strategic collaborations and licensing agreements with pharmaceutical and biotechnology firms, which may include upfront payments, milestone payments, and royalties on product sales. Additionally, Curis may receive research and development funding from partners to support its clinical trials and drug development efforts. The company's revenue model heavily relies on successful clinical trial outcomes and obtaining regulatory approval for its drug candidates.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges, characterized by persistent losses and negative equity. Despite a strong gross profit margin, the company's profitability is hindered by high operational costs and leverage issues, posing risks to financial stability. Cash flow management needs improvement to enhance liquidity and sustainability.

Income Statement

Neutral

The company's income statement reflects significant challenges with persistent negative EBIT and net income over recent years. The gross profit margin remains high at approximately 93.6% for TTM, indicating efficient cost management. However, the negative net profit margin of -444% for TTM highlights ongoing operational inefficiencies and substantial losses. Revenue growth over the period has been stagnant, showing a slight increase of 2.35% from the previous year to TTM. Overall, profitability remains a critical concern.

Balance Sheet

Negative

Curis exhibits a highly leveraged balance sheet with negative stockholders' equity in the TTM period, indicating potential financial instability. The debt-to-equity ratio is not calculable due to negative equity, suggesting high financial risk. The equity ratio is negative, which reflects the challenges in sustaining financial health. The company needs to address its liabilities to improve financial stability.

Cash Flow

Neutral

The cash flow statement shows a positive shift in investing cash flow for TTM, but operating cash flow remains negative, putting pressure on liquidity. The free cash flow growth rate is negative compared to prior periods, indicating cash constraints. The operating cash flow to net income ratio is positive, suggesting some alignment between operational activities and accounting earnings despite being negative.

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
10.26M	10.02M	10.16M	10.65M	10.84M	10.00M
	Gross Profit
9.60M	9.81M	9.90M	10.12M	10.30M	9.50M
	EBIT
-47.75M	-48.33M	-53.02M	-42.06M	-24.90M	-24.36M
	EBITDA
-46.54M	-45.14M	-50.51M	-39.98M	-24.67M	-27.17M
	Net Income Common Stockholders
-45.55M	-47.41M	-60.32M	-50.64M	-34.88M	-36.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
48.95M	56.33M	85.62M	139.85M	183.06M	20.54M
	Total Assets
58.82M	77.28M	108.85M	162.30M	204.36M	35.11M
	Total Debt
0.00	2.79M	6.74M	5.04M	7.66M	166.00K
	Net Debt
-11.47M	-23.89M	-12.92M	-34.97M	-121.95M	-15.26M
	Total Liabilities
5.26M	57.61M	62.30M	71.59M	73.69M	69.02M
	Stockholders Equity
53.56M	19.67M	46.55M	90.71M	130.67M	-33.91M
Cash Flow		Free Cash Flow
-40.49M	-38.43M	-54.75M	-37.62M	-26.42M	-26.25M
	Operating Cash Flow
-40.49M	-38.43M	-54.34M	-37.62M	-25.74M	-26.20M
	Investing Cash Flow
44.39M	37.79M	33.02M	-47.90M	-49.05M	-4.46M
	Financing Cash Flow
-7.51M	7.58M	867.00K	-4.17M	188.81M	23.27M

Curis Technical Analysis

Technical Analysis Sentiment

Negative

Last Price1.17

Price Trends

50DMA

2.65

Negative

100DMA

3.12

Negative

200DMA

4.27

Negative

Market Momentum

MACD

-0.28

Positive

RSI

14.27

Positive

STOCH

2.29

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.98, below the 50-day MA of 2.65, and below the 200-day MA of 4.27, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 14.27 is Positive, neither overbought nor oversold. The STOCH value of 2.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Risk Analysis

Curis disclosed 61 risk factors in its most recent earnings report. Curis reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Curis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (48)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
VVOS	45 Neutral	$13.49M	―	-266.25%	―	8.91%	70.18%
LSTA	41 Neutral	$16.82M	―	-51.43%	―	―	7.07%
CRIS	39 Underperform	$12.24M	―	-634.71%	―	8.83%	22.06%
UBX	34 Underperform	$16.19M	―	-148.97%	―	―	47.26%
BCAB	31 Underperform	$17.22M	―	-164.30%	―	―	44.38%
CVM	22 Underperform	$17.74M	―	-227.76%	―	―	30.96%

* Healthcare Sector Average

Performance Comparison

CRIS

Curis

1.17

-13.39

-91.96%

CVM

Cel-Sci

0.31

-1.28

-80.50%

LSTA

Lisata Therapeutics

1.95

-0.88

-31.10%

UBX

Unity Biotechnology

0.99

-0.51

-34.00%

VVOS

Vivos Therapeutics

2.33

-0.44

-15.88%

BCAB

BioAtla

0.30

-2.56

-89.51%

Curis Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: -49.57% | Next Earnings Date: May 7, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant progress in drug development with positive clinical data and regulatory advancements, alongside improved financial metrics. However, ongoing net losses and reliance on partnerships present challenges.

Highlights

Accelerated Approval Pathway for Emavusertib

The discussions with EMA and FDA were productive, leading to the potential for accelerated approval in the U.S. and conditional marketing authorization in Europe for emavusertib in combination with ibrutinib in PCNSL.

Orphan Drug Designation for Emavusertib

Emavusertib has been granted Orphan Drug Designation for primary CNS lymphoma in both the U.S. and Europe.

Positive Clinical Data in NHL and AML

In the TakeAim Lymphoma study, 6 out of 13 BTKI experienced patients and 5 out of 6 BTKI naïve patients showed objective responses. In AML, a 38% composite CR rate was achieved in FLT3 mutation patients.

Financial Improvements

Net loss decreased to $9.6 million in Q4 2024 from $117 million in Q4 2023. R&D and G&A expenses were also reduced.

Extended Cash Runway

Two offerings have extended Curis's cash runway into the fourth quarter of 2025.

Lowlights

Ongoing Net Loss

Curis reported a net loss of $43.4 million for the 12 months ended December 31, 2024, indicating ongoing financial challenges despite improvements.

Dependence on Future Partnerships

Curis is actively seeking partnerships to move forward with its programs, indicating a reliance on external collaborations for future progress.

Company Guidance

During Curis's Fourth Quarter 2024 Business Update Call, significant progress was reported, particularly in the TakeAim Lymphoma study evaluating emavusertib combined with ibrutinib for PCNSL. The study, with over 30 clinical sites open, aims to complete enrollment in 12 to 18 months, targeting accelerated approval pathways in the U.S. and Europe. Among 27 relapsed refractory PCNSL patients, notable responses were observed, including six objective responses in BTKI-experienced patients and five in BTKI-naïve patients. Additionally, the emavusertib study in AML showed a 38% composite CR rate in FLT3 mutation patients, with 10 objective responses in 19 evaluable patients. Financially, Curis reported a net loss of $9.6 million for Q4 2024, down from $117 million in 2023, with cash runway extended into Q4 2025 through recent offerings. The company remains optimistic about future developments and partnerships.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.